ArticleFrontiers in medicine2026
Application of oral sulfate solution combined with linaclotide in bowel preparation for colonoscopy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: High-quality bowel preparation is essential for accurate colonoscopy. Currently, linaclotide is used as an adjunctive agent supporting bowel preparation, but evidence for its combination with oral sulfate solution (OSS) remains limited. This study aimed to evaluate whether the addition of linaclotide to OSS could improve the efficacy of bowel preparation. Methods: This single-blind, randomized controlled trial enrolled outpatients scheduled for colonoscopy. Participants were randomly assigned (1:1:1) to one of three groups: the OSS + Linaclotide group, the OSS group, or the polyethylene glycol (PEG) group. The primary outcome was the adequate bowel preparation rate, while secondary outcomes included tolerability, colonoscopy findings, and safety. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) population, and safety was evaluated in the as-treated population. Results: A total of 370 patients were included in the mITT analysis. There was no statistically significant difference in the adequate bowel preparation rate between the OSS + Linaclotide group and the OSS group (86.5% vs. 88.0%; unadjusted relative risk [RR], 0.98; 95% confidence interval [CI], 0.89-1.08; Conclusion: This study did not meet its primary endpoint. Linaclotide added to OSS provided no additional cleansing efficacy over OSS alone or PEG. Exploratory analysis found that the combination may reduce bloating, a potential tolerability advantage requiring further verification in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.